Hunan Jiudian Pharmaceutical Co Ltd (300705) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hunan Jiudian Pharmaceutical Co Ltd (300705) has a cash flow conversion efficiency ratio of 0.068x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥180.33 Million ≈ $26.39 Million USD) by net assets (CN¥2.66 Billion ≈ $388.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Hunan Jiudian Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Hunan Jiudian Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Hunan Jiudian Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 300705 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Hunan Jiudian Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hunan Jiudian Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Keshun Waterproof Technologies Co Ltd Class A
SHE:300737
|
-0.064x |
|
AP (Thailand) Public Company Limited
BK:AP
|
0.039x |
|
ZKTECO Co. Ltd. A
SHE:301330
|
N/A |
|
JinkoSolar Holding Co. Ltd
F:ZJS1
|
0.075x |
|
Silicon Integrated Systems Corp
TW:2363
|
-0.001x |
|
Sgis Songshan Co Ltd
SHE:000717
|
0.093x |
|
United Overseas Australia Ltd
AU:UOS
|
0.030x |
|
Jiangxi Sanchuan Water Meter
SHE:300066
|
0.003x |
Annual Cash Flow Conversion Efficiency for Hunan Jiudian Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Hunan Jiudian Pharmaceutical Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Hunan Jiudian Pharmaceutical Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.53 Billion ≈ $369.74 Million |
CN¥746.36 Million ≈ $109.22 Million |
0.295x | +35.18% |
| 2023-12-31 | CN¥1.97 Billion ≈ $288.75 Million |
CN¥431.19 Million ≈ $63.10 Million |
0.219x | +26.13% |
| 2022-12-31 | CN¥1.55 Billion ≈ $227.20 Million |
CN¥268.99 Million ≈ $39.36 Million |
0.173x | -0.22% |
| 2021-12-31 | CN¥1.10 Billion ≈ $160.87 Million |
CN¥190.87 Million ≈ $27.93 Million |
0.174x | -3.27% |
| 2020-12-31 | CN¥835.68 Million ≈ $122.29 Million |
CN¥149.99 Million ≈ $21.95 Million |
0.179x | +50.70% |
| 2019-12-31 | CN¥761.87 Million ≈ $111.49 Million |
CN¥90.74 Million ≈ $13.28 Million |
0.119x | +25.36% |
| 2018-12-31 | CN¥718.16 Million ≈ $105.09 Million |
CN¥68.23 Million ≈ $9.98 Million |
0.095x | -21.99% |
| 2017-12-31 | CN¥660.26 Million ≈ $96.62 Million |
CN¥80.42 Million ≈ $11.77 Million |
0.122x | -28.61% |
| 2016-12-31 | CN¥323.43 Million ≈ $47.33 Million |
CN¥55.18 Million ≈ $8.07 Million |
0.171x | +34.88% |
| 2015-12-31 | CN¥254.51 Million ≈ $37.24 Million |
CN¥32.20 Million ≈ $4.71 Million |
0.126x | -11.82% |
| 2014-12-31 | CN¥209.87 Million ≈ $30.71 Million |
CN¥30.11 Million ≈ $4.41 Million |
0.143x | -17.81% |
| 2013-12-31 | CN¥175.85 Million ≈ $25.73 Million |
CN¥30.69 Million ≈ $4.49 Million |
0.175x | -- |
About Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. Its products portfolio includes Pantoprazole Sodium Enteric-coated, Ferrous Succinate, Rosuvastatin Calcium, Ebastine, and Rabeprazole Sodium Enteric-coated Tablets; and Acetylcysteine Granules, Potassium Sodium Hydrogen Citrate Granules, Loxoprofen Sodium Gel Pat… Read more